Amgen expects approval for Xgeva as bone treatment in April
Thousand Oaks-based Amgen said Aug. 22 that the U.S. Food and Drug Administration will likely make a decision by April 26, 2012 on the biotech firm’s application to expand the use of its Xgeva bone treatment drug to treat advanced prostate cancer. Amgen, the largest biotech company in the world, said in a statement that Read More →
Amgen gets sought-after FDA approval
The Food and Drug Administration has approved the use of Amgen’s bone drug denosumab in patients with certain types of cancer, Amgen announced Nov. 18.
FDA OKs Aranesp for pre-dialysis patients
Amgen’s anemia treatment Aranesp is safe for kidney patients whose disease doesn’t require dialysis, a federal panel announced Oct. 18 in response to a study that found the drug could increase stroke risk in those patients. Outside advisers to the U.S. Food and Drug Administration said the treatment shouldn’t be withdrawn or limited to a Read More →